This document outlines consensus-based clinical safety guidelines for high-dose ibogaine–assisted opioid detoxification, synthesizing decades of clinical experience and published research to standardize screening, dosing, cardiac monitoring, psychological risk management, and aftercare. It focuses on purified ibogaine hydrochloride, emphasizing QT-interval risk, drug interactions, patient selection, and supervised care environments, with the goal of reducing preventable adverse events and establishing minimum standards for clinical and research use.

This document, The Ibogaine Dossier / Manual for Ibogaine Therapy, is an early consensus-based safety and treatment manual that synthesizes decades of clinical observation, provider experience, and selected NIDA draft protocols to establish practical guidelines for ibogaine-assisted addiction interruption. It focuses heavily on risk reduction—screening, cardiac and laboratory testing, dosing ranges, monitoring, and aftercare—while acknowledging diverse provider philosophies, unresolved safety questions, and the absence of controlled trials. Rather than promoting ibogaine as a cure, the manual frames it as a powerful but high-risk intervention .

This practitioner memoir documents real-world ibogaine treatment practice from a non-medical provider, emphasizing informed consent, strict cardiac and liver screening, careful dosing, constant supervision, and set-and-setting as central to safety. Drawing on firsthand cases, it highlights gender differences in response, risks from comorbid conditions, and the limits of ibogaine as a stand-alone intervention, arguing that post-treatment support—especially body-based therapies and peer connection—is critical for sustaining recovery and preventing relapse.